News and resources | Resources
Infographic 23 February 2024

February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics

Downloads
Infographic
Share
Topics
COVID-19InnovationIntellectual propertyPandemic preparednessTechnology transferTrade

As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.

Related news and resources

Statement 22 Apr 2024

Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005)

On 22 April 2024, IFPMA delivered a statement at the Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.

Read more
Statement 9 Apr 2024

Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda

On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.

Read more
Statement 21 Mar 2024

9th Meeting of the Intergovernmental Negotiating Body (INB): Open session with relevant stakeholders focusing on critical elements for a pandemic agreement

  On 21 March 2024, Thomas Cueni, Director General, IFPMA delivered a statement at the 9th Meeting of the INB in an open session with relevant stakeholders focusing on critical elements for a pandemic agreement. IFPMA strongly supports the efforts to find agreement on a Pandemic Accord and we reaffirm our full commitment to constructively...

Read more
Top